EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Sulbactam–durlobactam and cefiderocol combination treatment of Burkholderia cenocepacia -associated Fitz–Hugh–Curtis syndrome

Bhavita Gaglani iD, Tessa M Andermann, Claire Wate, Jorge Oldan, Chirag S Desai, Steven H Marshall, Robert A Bonomo iD, Ray Coakley, David van Duin iD, Anne Lachiewicz

Antimicrobial Agents and Chemotherapy · 01.07.2026 · 70 (7)

DOI: 10.1128/aac.01542-25 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 01.07.2026. Verfasst von Bhavita Gaglani und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Anesthesiology, Wake Forest School of Medicine, Winston Salem, North Carolina, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Cephalosporins, Sulbactam, Burkholderia Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A 50-year-old woman with cystic fibrosis (CF) and lung transplantation developed persistent deep abscesses due to multidrug-resistant (MDR) Burkholderia cenocepacia, unresponsive to multiple antibiotics and surgeries. Combination therapy with sulbactam–durlobactam (SUL-DUR) and cefiderocol (FDC) along with surgical interventions led to clinical and radiographic stability. This report of a successful sulbactam–durlobactam and cefiderocol treatment highlights this targeted β-lactam-β-lactamase inhibitor combination as an option for refractory B. cepacia complex (BCC) infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsCephalosporinsSulbactamBurkholderia InfectionsBurkholderia cenocepaciaCefiderocolHumansFemaleMiddle AgedCystic FibrosisDrug Therapy, CombinationLung TransplantationDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

Burkholderia cepacia complexcefiderocolcystic fibrosislung transplantationmultidrug resistancesulbactam–durlobactam

Substanzen

CefiderocolAnti-Bacterial AgentsCephalosporinsSulbactam

Autor:innen und Institutionen

  • Department of Medicine and Anesthesiology, Wake Forest School of Medicine, Winston Salem, North Carolina, USA.
  • Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Institute of Global Health & Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Department of Radiology, Molecular Imaging and Therapeutics, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Division of Abdominal Transplant, Department of Surgery, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.

ORCID-Profile: Bhavita Gaglani, Robert A Bonomo, David van Duin

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Gaglani, B., Andermann, T. M., Wate, C., Oldan, J., Desai, C. S., Marshall, S. H., Bonomo, R. A., Coakley, R., van Duin, D., & Lachiewicz, A. (2026). Sulbactam–durlobactam and cefiderocol combination treatment of Burkholderia cenocepacia -associated Fitz–Hugh–Curtis syndrome. Antimicrobial Agents and Chemotherapy, 70(7). https://doi.org/10.1128/aac.01542-25

Vancouver

Gaglani B, Andermann TM, Wate C, Oldan J, Desai CS, Marshall SH, et al. Sulbactam–durlobactam and cefiderocol combination treatment of Burkholderia cenocepacia -associated Fitz–Hugh–Curtis syndrome. Antimicrobial Agents and Chemotherapy. 2026;70(7). doi:10.1128/aac.01542-25

BibTeX
@article{Gaglani2026,
  author = {Gaglani, Bhavita and Andermann, Tessa M and Wate, Claire and Oldan, Jorge and Desai, Chirag S and Marshall, Steven H and Bonomo, Robert A and Coakley, Ray and van Duin, David and Lachiewicz, Anne},
  title = {Sulbactam–durlobactam and cefiderocol combination treatment of Burkholderia cenocepacia -associated Fitz–Hugh–Curtis syndrome},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {7},
  doi = {10.1128/aac.01542-25}
}
Kostenlos starten →